Athletes will continue to be able to use weight-loss medication in 2027, although the World Anti-Doping Agency (Wada) will keep the drugs on its monitoring list.
Wada has concerns over the ability of weight-loss drugs such as semaglutide and tirzepatide - commonly referred to by brand names including Ozempic, Wegovy and Mounjaro - to aid performance.
